Key result
This editorial summarizes recent advancements and unmet needs in anticoagulation for cardiovascular diseases, highlighting the evolving role of DOACs and emerging factor XI/XII inhibitors.
No takes yet. Share an insight, caveat, or question.
Tuttolomondo et al. (2023) conducted an editorial in Cardiovascular diseases (thrombosis, atrial fibrillation, VTE, PAD). Anticoagulation (DOACs, VKAs, FXI/FXII inhibitors) was evaluated. This editorial summarizes recent advancements and unmet needs in anticoagulation for cardiovascular diseases, highlighting the evolving role of DOACs and emerging factor XI/XII inhibitors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: